New face for a familiar friend: The deGramont regimen in the treatment of metastatic colorectal cancer given as an outpatient: A feasibility study

Journal of Oncology Pharmacy Practice

Volumn 8, Issue 2-3, 2002, Pages 97-103

  Rowe, Michelle ^a   Walle, Juan W ^a   Swindell, Ric ^a   Fitzsimmons, Lesley ^a   James, Roger D ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b MAIDSTONE HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Colorectal cancer; deGramont; Outpatient treatment

Indexed keywords

CISPLATIN; ELASTOMER; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CENTRAL VENOUS CATHETER; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG DELIVERY SYSTEM; DRUG STABILITY; FEASIBILITY STUDY; FEMALE; HOME CARE; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; MALE; METASTASIS; OUTPATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; STANDARD;

EID: 0036992924     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155202jp092oa     Document Type: Article

References (11)

1. Baranowski L. Central venous access devices: current technologies, uses and management strategies. J Intravenous Nurs 1993; 16: 167-94.
2. Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7: 425-32.
3. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997: 15: 261-67.
4. de Gramont A, Krulik M, Cady J, et al. High-dose folinic acid and5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol 1988; 24: 1499-503.
5. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808-15.
6. Fitzsimmons CL, Gilleece MH, Ranson MR, et al. Central nervous catheter placement: extending the role of the nurse. J R Coll Physicians Lond 1997; 31: 533-35.
7. Seymour M, Wilson G, Dent J, et al. Dose-escalation study of a modified "de Gramont" regimen, better suited to the chemotherapy day unit. Ann Oncol 1998; 9: 47.
8. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group [see comments]. N Engl J Med 2000; 343: 905-14.
9. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-47.
10. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
11. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-47.